Street Calls of the Week
Director James Mulay of CG Oncology, Inc. (NASDAQ:CGON) sold 22,686 shares of common stock on September 18 and 19, 2025, for approximately $884,909. The shares were sold at prices ranging from $38.99 to $39.01. According to InvestingPro data, CGON’s stock has shown strong momentum with a 36% gain over the past six months, though current technical indicators suggest the stock is in overbought territory.
On the same dates, Mulay exercised options to acquire 22,686 shares of CG Oncology common stock at a price of $1.82, for a total value of $41,288.
The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.99 to $39.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Fully vested
In other recent news, CG Oncology has been in the spotlight with notable updates concerning its bladder cancer treatment, cretostimogene. The company reported that its Phase 3 BOND-003 Cohort C study showed a 41.8% complete response rate at 24 months for patients with high-risk non-muscle invasive bladder cancer. This data, which will be presented at an upcoming medical meeting, highlights that 46 out of 110 patients maintained a complete response, indicating significant durability of the treatment. Analyst firms have responded positively, with H.C. Wainwright reiterating a Buy rating and a $75.00 price target, citing the strong clinical data. Similarly, Jones Trading initiated coverage with a Buy rating and a $50.00 price target, focusing on the potential of cretostimogene. Additionally, H.C. Wainwright addressed inquiries about the pricing of Inlexzo, a product from Johnson & Johnson, which is expected to be around $69,000 per dose. These developments underscore the growing interest and confidence in CG Oncology’s cancer treatment advancements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.